secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001099800-26-000002
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FTC injunction blocks Edwards' JenaValve acquisition; Edwards raises FY2026 EPS guidance to $2.90-$3.05
--------------------------------------------------------------------------------

- US District Court grants FTC motion for injunction blocking Edwards' acquisition of JenaValve; deal terminated.
- Edwards revises FY2026 adjusted EPS guidance upward to $2.90-$3.05 from $2.80-$2.95.
- Edwards disagrees with ruling, remains committed to AR therapy; advancing SOJOURN valve and JOURNEY trial.
- Additional updates expected at Q4 earnings call in February.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980026000002/0001099800-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980026000002/ew-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001099800-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer